Figure 7.

Local gene transfer of GLO1 or augmentation of GLO1 by coformulation of tRES- and HESP-improved diabetic wound healing. A: Wound closure curves in db/db mice that received local gene transfer (n = 5 per group). *P < 0.05, **P < 0.01 vs. db/db plus Ad-GFP. B: Capillary formation as evaluated by CD31 staining (brown) in wounds receiving gene transfer. The arrows indicate capillary-like structures at wound edge. Images on the right are amplified from the region marked with a square on the left. C: Representative images of cutaneous wounds. D: GLO1 expression levels in tissue at the edge of wounds in db/db mice that received gene transfer (n = 5 per group). *P < 0.05 vs. db/db plus Ad-GFP. E: Wound closure curves in db/db mice that received tRES-HESP coformulation or vehicle control (0.002% DMSO). *P < 0.05 vs. db/db plus control, **P < 0.01 vs. control. F: Capillary formation as evaluated by CD31 staining (brown) in wounds. The arrows indicate capillary-like structures at wound edge. Images on the right are amplified from the region marked with a box on the left. G: Representative images of cutaneous wounds. H: GLO1 expression level in tissue at the edge of wounds that received tRES-HESP therapy (n = 5 per group). *P < 0.05 vs. control. I: Luciferase promoter reporter assay of transcriptional activity of GLO1 in db/db BMPCs treated with tRES-HESP coformulation showed that tRES-HESP enhanced GLO1 promotor activity (n = 5 per group). *P < 0.05 vs. control. Shown above the dot plot is the structure of LightSwitch Promoter Reporter with precloned oligonucleotides of human GLO1 promoter. M, protein marker.